上海莱士(002252.SZ)：SR604注射液新增临床试验适应症申请获受理

Core Viewpoint - The company has received a notice from the National Medical Products Administration, approving the clinical trial application for the SR604 injection to treat bleeding episodes in patients with vascular hemophilia [1] Group 1 - The SR604 injection is a humanized high-affinity monoclonal antibody that specifically inhibits the anticoagulant function of human activated protein C [1]